This feature is going to take a closer look at five (5) stocks look now!

Catheter Precision Inc. (NYSEAMERICAN: VTAK) The United States-based medical device company is best known for its work on improving the lives of people suffering from cardiac arrhythmias. On October 12, 2023, Catheter Precision announced that its VIVO™ (View into Ventricular Onset) 3D mapping system had been awarded national reimbursement in the United Kingdom (UK) under the provisions of the High-Cost Tariff Excluded Devices (HCTED).

VIVO™ helps physicians figure out the origins of ventricular arrhythmias prior to procedures. HCTED is a supply and purchase system that the National Health Service England (NHS England) instituted to pay for such products that qualify for separate payment from the national budget dedicated to medical procedures. Hospitals would be able to bill the use of a single-use product like the VIVO™3D mapping system straight to the National Health Service England (NHS England).

The company showcased its VIVO™ 3D mapping system the 18th Annual International Symposium on Ventricular Arrhythmias: Pathophysiology and Therapy, on Friday and Saturday, October 13–14, 2023, at the Bellevue Hotel Philadelphia where 200 participants were in attendance. Furthermore, Catheter Precision Inc.’s VIVO™ 3D mapping system will be showcased at several electrophysiology conferences in 2023.

Momentus Inc. (NASDAQ: MNTS) is a United States-based commercial space company known for providing satellite buses, transportation, and a range of infrastructure services for space. The company also offers Delta-V delivery for missions that need precise custom orbits. On October 11, Momentus Inc. announced that it had signed a contract with RIDE! Space for transportation as well as orbital delivery of services.

The delivery would take place at some point in the first quarter of 2024. In the news release, the company also noted that RIDE! Space would be flying its Djibouti and Gaindesat payloads on one mission. Momentus would be a party to a historic moment for the African space sector. As per a report released in August by the African Space Industry Annual Report, the space economy on the continent had been projected to touch $22 billion by 2026. Ride-sharing services could well prove to be a major component of that growth.

Mereo BioPharma Group Plc (NASDAQ: MREO) The biopharmaceutical company is involved in the development of path-breaking therapeutics for rare diseases. On October 14, Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group Plc jointly announced the interim data from Phase 2 of the Phase 2/3 Orbit study. The study was related to the demonstration that treatment with setrusumab could help in a significant reduction of fracture incidents in patients suffering from OI.

The date pertaining to the study was showcased at the American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR). Additionally, it was noted that there was at least six months of follow-up treatment, and the subjects continued to show improvements. The fracture rate, when annualized, was reduced by as much as 67% in the 24 patients who had been a part of the Phase 2 part of the study. In the two years prior to the commencement of the study, all of the patients had experienced at least one fracture.

Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is a clinical-stage biotech company involved in the development of advanced chemotherapeutic products meant to improve the safety and effectiveness of cancer treatments.

On October 13, Processa Pharmaceuticals Inc. announced that George NG, its Chief Executive Officer, would make a presentation at the ThinkEquity Conference on October 19, 2023, about the updated company overview. The event would be held at the Mandarin Oriental Hotel in New York, and NG’s presentation would begin at 4:30 eastern time at the Lotus Suite East.

Matinas BioPharma (NASDAQ: MTNB) is a clinical-stage biopharmaceutical firm that focuses on the delivery of path-breaking therapies through its lipid nanocrystal platform delivery technology. On October 11, Matinas BioPharma came into focus after it announced that it had been successful in bringing about complete clinical resolution of recurrent hemorrhagic cystitis in a patient brought about by Candida crusei with the treatment by MAT2203.

MAT2203 had been synthesized with the potent antifungal amphotericin in the form of an oral formulation. The patient had been treated by Marisa H. Miceli under the company’s Matinas’ Expanded Access/Compassionate Use Program. Miceli is an MD and Professor of Medicine with a specialization in Fungal Infection and Transplant Diseases at the University of Michigan’s Division of Infectious Diseases, Internal Medicine. The company went on to announce that, in total, 11 patients were receiving treatment or had completed treatment under the program.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com